Systematic use of transradial PCI in patients with ST-segment elevation myocardial infarction: A call to "arms"

Mackram Eleid, Charanjit Rihal, Rajiv Gulati, Malcolm R. Bell

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A growing body of evidence now supports the use of transradial percutaneous intervention (TRI) as the preferred access site for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Historically, TRI has been avoided in the STEMI population due to concerns over longer procedure time, longer door-to-device time, higher crossover rates, and the experience level required with TRI compared with transfemoral access. However, in recent years, recognition of the impact of periprocedural bleeding on mortality in patients with acute coronary syndromes has garnered interest in the utility of TRI as an established method to reduce bleeding. Registry data, meta-analyses, and randomized control trials all similarly demonstrate that TRI is associated with reduced periprocedural bleeding and lower mortality compared with transfemoral access in the STEMI population. Additional benefits of TRI include enhanced patient comfort, reduced hospital length of stay, and reduced cost. Despite the evidence, trends in use of TRI in the United States have shown a slow adoption rate as a result of multiple barriers in clinical practice and doubts about the mechanism and causal relationship of mortality reduction with TRI. We summarize the current evidence and propose a call to action to foster training of TRI in cardiovascular fellowship programs and post-fellowship courses, and for more widespread implementation of TRI in STEMI patients.

Original languageEnglish (US)
Pages (from-to)1145-1148
Number of pages4
JournalJACC: Cardiovascular Interventions
Volume6
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Hemorrhage
Mortality
Length of Stay
Acute Coronary Syndrome
Population
Registries
Meta-Analysis
Costs and Cost Analysis
Equipment and Supplies
ST Elevation Myocardial Infarction
Therapeutics
Patient Comfort

Keywords

  • PCI
  • STEMI
  • transradial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Systematic use of transradial PCI in patients with ST-segment elevation myocardial infarction : A call to "arms". / Eleid, Mackram; Rihal, Charanjit; Gulati, Rajiv; Bell, Malcolm R.

In: JACC: Cardiovascular Interventions, Vol. 6, No. 11, 11.2013, p. 1145-1148.

Research output: Contribution to journalArticle

@article{565034b882c949609d98e167019b5a73,
title = "Systematic use of transradial PCI in patients with ST-segment elevation myocardial infarction: A call to {"}arms{"}",
abstract = "A growing body of evidence now supports the use of transradial percutaneous intervention (TRI) as the preferred access site for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Historically, TRI has been avoided in the STEMI population due to concerns over longer procedure time, longer door-to-device time, higher crossover rates, and the experience level required with TRI compared with transfemoral access. However, in recent years, recognition of the impact of periprocedural bleeding on mortality in patients with acute coronary syndromes has garnered interest in the utility of TRI as an established method to reduce bleeding. Registry data, meta-analyses, and randomized control trials all similarly demonstrate that TRI is associated with reduced periprocedural bleeding and lower mortality compared with transfemoral access in the STEMI population. Additional benefits of TRI include enhanced patient comfort, reduced hospital length of stay, and reduced cost. Despite the evidence, trends in use of TRI in the United States have shown a slow adoption rate as a result of multiple barriers in clinical practice and doubts about the mechanism and causal relationship of mortality reduction with TRI. We summarize the current evidence and propose a call to action to foster training of TRI in cardiovascular fellowship programs and post-fellowship courses, and for more widespread implementation of TRI in STEMI patients.",
keywords = "PCI, STEMI, transradial",
author = "Mackram Eleid and Charanjit Rihal and Rajiv Gulati and Bell, {Malcolm R.}",
year = "2013",
month = "11",
doi = "10.1016/j.jcin.2013.08.002",
language = "English (US)",
volume = "6",
pages = "1145--1148",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Systematic use of transradial PCI in patients with ST-segment elevation myocardial infarction

T2 - A call to "arms"

AU - Eleid, Mackram

AU - Rihal, Charanjit

AU - Gulati, Rajiv

AU - Bell, Malcolm R.

PY - 2013/11

Y1 - 2013/11

N2 - A growing body of evidence now supports the use of transradial percutaneous intervention (TRI) as the preferred access site for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Historically, TRI has been avoided in the STEMI population due to concerns over longer procedure time, longer door-to-device time, higher crossover rates, and the experience level required with TRI compared with transfemoral access. However, in recent years, recognition of the impact of periprocedural bleeding on mortality in patients with acute coronary syndromes has garnered interest in the utility of TRI as an established method to reduce bleeding. Registry data, meta-analyses, and randomized control trials all similarly demonstrate that TRI is associated with reduced periprocedural bleeding and lower mortality compared with transfemoral access in the STEMI population. Additional benefits of TRI include enhanced patient comfort, reduced hospital length of stay, and reduced cost. Despite the evidence, trends in use of TRI in the United States have shown a slow adoption rate as a result of multiple barriers in clinical practice and doubts about the mechanism and causal relationship of mortality reduction with TRI. We summarize the current evidence and propose a call to action to foster training of TRI in cardiovascular fellowship programs and post-fellowship courses, and for more widespread implementation of TRI in STEMI patients.

AB - A growing body of evidence now supports the use of transradial percutaneous intervention (TRI) as the preferred access site for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Historically, TRI has been avoided in the STEMI population due to concerns over longer procedure time, longer door-to-device time, higher crossover rates, and the experience level required with TRI compared with transfemoral access. However, in recent years, recognition of the impact of periprocedural bleeding on mortality in patients with acute coronary syndromes has garnered interest in the utility of TRI as an established method to reduce bleeding. Registry data, meta-analyses, and randomized control trials all similarly demonstrate that TRI is associated with reduced periprocedural bleeding and lower mortality compared with transfemoral access in the STEMI population. Additional benefits of TRI include enhanced patient comfort, reduced hospital length of stay, and reduced cost. Despite the evidence, trends in use of TRI in the United States have shown a slow adoption rate as a result of multiple barriers in clinical practice and doubts about the mechanism and causal relationship of mortality reduction with TRI. We summarize the current evidence and propose a call to action to foster training of TRI in cardiovascular fellowship programs and post-fellowship courses, and for more widespread implementation of TRI in STEMI patients.

KW - PCI

KW - STEMI

KW - transradial

UR - http://www.scopus.com/inward/record.url?scp=84888107848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888107848&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2013.08.002

DO - 10.1016/j.jcin.2013.08.002

M3 - Article

C2 - 24262613

AN - SCOPUS:84888107848

VL - 6

SP - 1145

EP - 1148

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 11

ER -